Laurie McGinley

Washington, D.C.

Reporter covering health and medicine

Education: Syracuse University, BS in journalism

Laurie McGinley covers health and medicine for The Washington Post. She focuses on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health, science and environment editor.
Latest from Laurie McGinley

The new face of Alzheimer’s: Early stage patients who refuse to surrender

For years, doctors and patients thought there was little to do when dementia was diagnosed, even at an early stage. Now, potentially sweeping changes loom.

April 24, 2023

White House plans to nominate cancer center chief to lead NIH

The National Institutes of Health has not had a permanent director since December 2021, when its longtime leader stepped down.

April 19, 2023

FDA backs second omicron booster for high-risk groups

The shots would be available for people who are at least 65 years old or immune-compromised.

April 18, 2023

Unpacking the flawed science cited in the Texas abortion pill ruling

Texas judge ignored scientific evidence of abortion pill’s safety, citing statistics that overstate the negative physical and psychological effects of mifepristone.

April 13, 2023

White House prepares for legal and political battle on abortion pill

The Biden administration seeks to reassure abortion rights supporters without running afoul of the courts after conflicting rulings on mifepristone.

April 12, 2023

Texas abortion pill ruling threatens FDA

"This opens the door to the courts’ second-guessing any FDA approval — especially for drugs for controversial areas like gender-affirming care," expert says.

April 7, 2023

Can I still get a medication abortion?

The answer is complicated and likely dependent on where you live, after dueling decisions by federal judges in Texas and Washington.

April 7, 2023

FDA yanks approval of Makena, only drug cleared to lower preterm birth

The FDA concluded there is no evidence that the drug, which had been cleared by the agency through accelerated approval in 2011, works.

April 6, 2023

FDA to okay second omicron-targeting booster for some, officials say

The Biden administration is moving to make the shot available for older people and those with impaired immune systems.

April 3, 2023

Abortion pill fight may have broader implications for FDA drug approval

A federal judge is being asked in a lawsuit to direct the agency to rescind its approval of mifepristone, one of two drugs used in medication abortions — a move that would be unprecedented.

March 15, 2023